Market Overview

UPDATE: Citigroup Upgrades Biogen Idec to Buy on Strong Fundamentals

Share:
Related BIIB
Despite Drug Trial Miss, Here's Why Biogen Should Trade Higher
Technical Alert: Biogen Inc. Higher Off Trial Results For Aducanumab
Biogen Underplays Promising Alzheimer's Data On Seizure Worries (Investor's Business Daily)

Citigroup upgraded Biogen Idec (NASDAQ: BIIB) from Neutral to Buy and raised the price target from $160.00 to $187.00.

Citigroup commented, "We are upgrading Biogen to Buy as we simply do not see a better entry point anytime soon. We have been on the sidelines hoping to find material weakness, but alas, the fundamentals are too strong and recent PEG-Avonex positive ph 3 data and Tysabri acq from Elan should lead to sustainable upside relative to expectations. We expect that Biogen will come to dominate the MS market in the same way that Gilead dominates HIV and this should lead to tremendous operating synergy and margin expansion. Along with a deep mid-stage pipeline, Biogen should provide sustainable long-term revs/EPS growth."

Biogen Idec closed at $161.75 on Thursday.

Latest Ratings for BIIB

DateFirmActionFromTo
Nov 2016MizuhoInitiates Coverage OnNeutral
Nov 2016PiperJaffrayUpgradesNeutralOverweight
Nov 2016Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!